Patients with advanced NSCLC treated with nivolumab (anti-PD-1) in a phase I clinical trial showed a 5-year OS rate of 16%, quadrupling survival with standard CT [60]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.